Biotechnology

Willkie has extensive experience in the health care and life sciences field, both in the United States and abroad. We represent companies and investors in the areas of biotechnology, pharmaceuticals, medical technology, wellness and providers. Our work includes corporate transactions, mergers and acquisitions, joint venture transactions, compliance matters, IP issues, patent litigation and counseling, and general litigation.

Willkie has extensive experience in the health care and life sciences field, both in the United States and abroad. We represent companies and investors in the areas of biotechnology, pharmaceuticals, medical technology, wellness and providers. Our work includes corporate transactions, mergers and acquisitions, joint venture transactions, compliance matters, IP issues and general litigation.

Capital Markets

  • Athersys, Inc.: Represented ING Barings (Furman Selz) in a private placement of $10 million of Class C convertible preferred stock of Athersys, a clinical stage biopharmaceutical and genomics company.

    Clovis Oncology: Represented this developer and marketer of anti-cancer drugs since its inception and in various acquisition-related transactions, principal licensing agreements and the following financings:

    • $90 million public offering of common stock.
    • $250 million 144A offering of convertible senior notes.
    • $300 million underwritten public offering of convertible senior notes.
    • $100 million underwritten public offering of common stock.
    • $235.75 million underwritten public offering of common stock.
    • $345 million underwritten public offerings of common stock.
    • $287.5 million 144A offering of convertible senior notes.
    • $275 million underwritten public offering of common stock.

    Epigenomics AG: Represented Morgan Stanley Bank AG on the rights issue of German molecular diagnostics company Epigenomics, a developer and commercializer of proprietary products for the screening and diagnosis of cancer.

    IPF Partners: Represented IPF Partners in a venture bond financing for French clinical stage biopharmaceutical company Adocia.

- Collapse

Litigation and Investigation

  • SeraCare Life Sciences, Inc.: Conducted an internal investigation on behalf of the Audit Committee of SeraCare.

- Collapse

Mergers & Acquisitions, PE & VC Investments, Joint Ventures and Other Business Combinations

  • Aegerion/Novelion Therapeutics/Amryt Pharma: Represented global biopharmaceutical company Aegerion Pharmaceuticals, Inc., a wholly owned subsidiary of Novelion Therapeutics, in its recapitalization, whereby Amryt Pharma Plc agreed to acquire 100% of Aegerion’s reorganized stock.

    Constellation Pharmaceuticals/MorphoSys: Represented Constellation Pharmaceuticals in connection with MorphoSys’s acquisition of Constellation Pharmaceuticals.

    Ekkio/Q-Biologicals: Represented Ekkio and its portfolio company, Amatsigroup, in the acquisition of Q-Biologicals, a leading provider of process development and biomanufacturing services.

    Galil Medical/BTG: Represented certain shareholders of cryotherapy company Galil Medical in its sale to BTG plc.

    Hansen Medical/Auris Surgical Robots: Advised funds owned by Oracle Management and other majority stockholders of Hansen Medical, Inc. in the acquisition of Hansen Medical by Auris Surgical Robotics, Inc., as well as the related re-investment by such stockholders of their proceeds into Auris.

    NextPharma/Lonza: Represented NextPharma on its agreement to acquire the Ploermel and Edinburgh production sites of biotechnology company Lonza.

    Tikehau/Cisbio Bioassays/Abenex: Represented Tikehau on the financing aspects of the acquisition of Cisbio Bioassays by Abenex.

- Collapse